SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

business symbol for teamwork as abstract symbol
FDA
FDA’s Lost Leaders: Where Are They Now?
After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have landed new roles—at Eli Lilly, Pfizer, Iovance and more. The FDA’s loss, it seems, is largely the pharmaceutical industry’s gain.
October 20, 2025
 · 
8 min read
 · 
Heather McKenzie
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
Johnson & Johnson has yet to make a drug pricing deal with Trump; Novo makes more moves under new CEO; more than 1,000 laid off from CDC, though many immediately hired back; the BIOSECURE Act is back and more.
October 15, 2025
 · 
1 min read
 · 
Heather McKenzie
Same goal. Two businesses on the growth graph. vector
FDA
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
Heading into the final quarter of a year that has seen dramatic upheaval at the FDA—from the exodus of numerous senior leaders to unclear policy changes and a safety saga that engulfed the gene therapy space—drug approvals appear roughly on par with recent years.
October 13, 2025
 · 
4 min read
 · 
Heather McKenzie
Podcast
Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
The U.S. government remains shut down, with the FDA closed for new drug applications until further notice; cell and gene therapy leaders gather for the annual meeting in Phoenix with the field in a state of flux; Pfizer and Amgen will make drugs available at a discount as President Donald Trump’s tariffs still loom; and new regulatory documents show how Pfizer beat out the competition for Metsera.
October 8, 2025
 · 
1 min read
 · 
Heather McKenzie
Regulatory
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator
Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.
October 7, 2025
 · 
1 min read
 · 
Heather McKenzie
Pictured: CDC signage at its headquarters in Georg
CDC
CDC Adopts ACIP Recommendations on Chickenpox, COVID-19 Vaccines
A new group of CDC advisors voted last month to separate the chickenpox vaccine from the measles, mumps, rubella components of the MMRV shot due to concerns over febrile seizures, while recommending a more risk-based approach to COVID-19 immunizations that mirrors recent FDA approvals.
October 6, 2025
 · 
1 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building
Government
US Government Shuts Down, FDA Closed for New Applications
Due to policies regarding industry user fees, the FDA will not be able to accept any new drug applications for the duration of the government shutdown, according to Leerink Partners.
October 1, 2025
 · 
4 min read
 · 
Annalee Armstrong
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
M&A headlined for a second straight week as Genmab acquired Merus for $8 billion; Pfizer strikes most-favored-nation deal with White House; CDER Director George Tidmarsh caused a stir with a now-deleted LinkedIn post; GSK CEO Emma Walmsley will step down from her role; and uniQure’s gene therapy offers new hope for patients with Huntington’s disease.
October 1, 2025
 · 
2 min read
 · 
Heather McKenzie
Pictured: uniQure headquarters in Amsterdam
Huntington’s disease
UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout
If approved, uniQure’s gene therapy AMT-130—which slowed disease progression by 75%—would be the first genetic treatment for Huntington’s disease. A BLA submission is planned for the first quarter of 2026.
September 24, 2025
 · 
2 min read
 · 
Heather McKenzie
Podcast
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
The FDA is hoping to repurpose GSK’s Wellcovorin for cerebral folate deficiency; Pfizer acquired fast-moving weight-loss startup Metsera for nearly $5 billion after suffering a hat trick of R&D failures; psychedelics are primed for M&A action and Eli Lilly may be next in line; RFK Jr.’s revamped CDC advisory committee met last week with confounding results; and Stealth secured its Barth approval.
September 24, 2025
 · 
2 min read
 · 
Heather McKenzie
An umbrella protects the human brain from negative influences. Art collage.
Psychedelics
Psychedelics Space Enters New Era as AbbVie Dives In
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
September 22, 2025
 · 
6 min read
 · 
Heather McKenzie
Business vision and opportunity and determination. Businessman standing on cliff edge looking ahead. vector
Rare diseases
Stealth Wins Expedited FDA Nod for First-Ever Barth Syndrome Treatment
A decade-long journey has come to an end for Stealth BioTherapeutics and the Barth syndrome community with the first-ever treatment for this uncommon mitochondrial disease. CEO Reenie McCarthy called it a “pivotal victory” that “offers hope for expedited regulatory attention to other ultra-rare diseases.”
September 21, 2025
 · 
7 min read
 · 
Heather McKenzie
Cardiovascular disease
Deep Dive: Oral Obesity Drugs on the Cusp
In this deep dive, BioSpace explores the next big thing in obesity.
September 18, 2025
 · 
3 min read
 · 
Heather McKenzie
CDC
Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy
During a hearing in front of the Senate’s HELP committee, Susan Monarez addressed her controversial firing and recalled a conversation where Health Secretary Robert F. Kennedy Jr. allegedly said that “CDC employees were killing children and they don’t care.”
September 17, 2025
 · 
4 min read
 · 
Heather McKenzie
Podcast
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others abandon the U.K. after the introduction of a sizeable levy; Novo CEO Maziar Mike Doustdar lays off 9,000 while the company presents new data at EASD; Capsida loses a patient in a gene therapy trial; and CDER Director George Tidmarsh walks back comments on FDA adcomms.
September 17, 2025
 · 
2 min read
 · 
Heather McKenzie
Load More